← Back to Clinical Trials
Recruiting NCT07086118

Dexamethasone Versus Metoclopramide for Prophylaxis of Nausea and Vomiting After Cataract Surgery

Trial Parameters

Condition Cataract
Sponsor Alexandria University
Study Type INTERVENTIONAL
Phase N/A
Enrollment 210
Sex ALL
Min Age 40 Years
Max Age 80 Years
Start Date 2025-05-01
Completion 2025-09-01
Interventions
0.9% normal salineMetoclopramide 10mgDexamethasone

Brief Summary

Postoperative nausea and vomiting (PONV) is a common consequence of ambulatory surgery, affecting up to 80% of high-risk patients and 20-30% overall. Despite being widespread, a prior survey found that patients are more averse to PONV than pain and other significant postoperative problems. Furthermore, even mild cases of PONV can have serious repercussions, such as postanesthesia care unit (PACU) workflow disruption, delayed discharges, higher medical costs, and lower patient satisfaction.PONV following intraocular surgery can be unpleasant and may lead to serious complications including suprachoroidal hemorrhage (SCH). SCH is a potentially serious condition that occurs when the posterior ciliary arteries or vortex veins burst, resulting in blood in the suprachoroidal region. The hypothesis is that dexamethasone will lower the incidence of PONV after cataract surgery when compared with metoclopramide.

Eligibility Criteria

Inclusion Criteria: * Age: 40-80 years, both sexes. * ASA physical status class I to III. Exclusion Criteria: * history of motion sickness * patients with gastrointestinal disorders or gastro-oesophageal reflux * patients taking medications with known antiemetic activity * previous postoperative vomiting * allergy to bupivacaine * allergy to metoclopramide or dexamethasone

Related Trials